Ion channels as potential targets for the treatment of depression

Current Opinion in Drug Discovery and Development

Volumn 11, Issue 5, 2008, Pages 633-641

  Lodge, N J ^a   Li, Y W ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Calcium channel; Depression; Glutamatergic; Ion channel; Nicotinic; Potassium channel; Purinergic; Serotonergic

Indexed keywords

2 AMINO 4 METHYL 5 PHOSPHONO 3 PENTENOIC ACID; 4 BENZYL ALPHA (4 HYDROXYPHENYL) BETA METHYL 1 PIPERIDINEPROPANOL; AMITRIPTYLINE; AMPA RECEPTOR; AMPA RECEPTOR AGONIST; CALCIUM CHANNEL N TYPE; CITALOPRAM; DIZOCILPINE; IMIPRAMINE; ION CHANNEL; KETAMINE; LAMOTRIGINE; LITHIUM; MECAMYLAMINE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NICOTINE; NICOTINIC AGENT; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR BLOCKING AGENT; PAROXETINE; PLACEBO; POTASSIUM CHANNEL; PURINERGIC P2X2 RECEPTOR; SEROTONIN 3 RECEPTOR; TRAXOPRODIL; TWIK RELATED POTASSIUM CHANNEL 1; UNCLASSIFIED DRUG; UNINDEXED DRUG; VOLTAGE GATED CALCIUM CHANNEL;

ANIMAL BEHAVIOR; CLINICAL TRIAL; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SPECIFICITY; GENETIC ASSOCIATION; HUMAN; MAJOR DEPRESSION; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; SYMPTOM;

ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DRUG DESIGN; HUMANS; ION CHANNEL GATING; ION CHANNELS; LIGANDS; MEMBRANE TRANSPORT MODULATORS;

EID: 50249130275     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (78)

1. Ghosh A, Hellewell JS: A review of the efficacy and tolerability of agomelatine in the treatment of major depression. Expert Opin Investig Drugs (2007) 16(12):1999-2004.
2. Gaynes BN, Rush AJ, Trivedi MH, Wisniewski SR, Spenser D, Fava M: The STAR*D study: Treating depression in the real world. Cleveland Clin J Med (2008) 75(1):57-66.
3. Mathew SJ, Manji HK, Charney DS: Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacol (2008) 33(9):2080-2092.
4. Papp M, Moryl E: Antidepressant activity of non-competitive and competitive NMDA receptor antagonists in a chronic mild stress model of depression. Eur J Pharmacol (1994) 263(1-2):1-7.
5. Yilmaz A, Schulz D, Aksoy A, Canbeyli R: Prolonged effect of an anesthetic dose of ketamine on behavioral despair. Pharmacol Biochem Behav (2002) 71(1-2):341-344.
6. Maeng S, Zarate CA Jr, Du J, Schloesser RJ, McCammon J, Chen G, Manji HK: Cellular mechanisms underlying the antidepressant effects of ketamine: Role of α-amino-3-hydroxy-5-ethylisoxazole-4-propionic acid receptors. Biol Psychiatry (2008) 63(4):349-352. • Describes the role of AMPA receptors in ketamine-evoked antidepressant effects.
7. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JS: Antidepressant effects of ketamine in depressed patients. Biol Psychiatry (2000) 47(4):351-354. • The first paper to describe the rapid onset and prolonged antidepressant effects of ketamine in depressed patients.
8. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK: A randomized trial of an N-methyl- D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry (2006) 63(8):856-864. • Presents a randomized, placebo-controlled, double-blind crossover study in which a single sub-anesthetic dose of ketamine produced a rapid onset and prolonged antidepressant effect. This study confirmed and extended the original findings of Berman and colleagues, described in reference [7•].
9. Moghaddam B, Adams B, Verma A, Daly D: Activation of glutamatergic neurotransmission by ketamine: A novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci (1997) 17(8):2921-2927.
10. Chizh BA: Low dose ketamine: A therapeutic and research tool to explore N-methyl-D-aspartate (NMDA) receptor-mediated plasticity in pain pathways. J Psychopharmacol (2007) 21(3):259-271.
11. Herd DW, Anderson BJ, Holford NH: Modeling the norketamine metabolite in children and the implications for analgesia. Paediatr Anaesth (2007) 17(9):831-840.
12. Pittenger C, Duman RS: Stress, depression, and neuroplasticity: A convergence of mechanisms. Neuropsychopharmacology (2008) 33(1):88-109.
13. Garcia LS, Comim CM, Valvassori SS, Réus GZ, Barbosa LM, Andreazza AC, Stertz L, Fries GR, Gavioli EC, Kapczinski F, Quevedo J: Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus. Prog Neuropsychopharm Biol Psychiatry (2008) 32(1):140-144.
14. Anand A, Charney DS, Oren DA, Berman RM, Hu XS, Cappiello A, Krystal JH: Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: Support for hyperglutaminergic effects of N-methyl-D- aspartate receptor antagonists. Arch Gen Psychiatry (2000) 57(3):270-276.
15. Deakin JF, Lees J, McKie S, Hallak JE, Williams SR, Dursun SM: Glutamate and the neural basis of the subjective effects of ketamine: A pharmaco-magnetic resonance imaging study. Arch Gen Psychiatry (2008) 65(2):154-164.
16. Barbosa L, Berk M, Vorster M: A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. J Clin Psychiatry (2003) 64(4):403-407.
17. Ferguson JM, Shingleton RN: An open-label, flexible-dose study of memantine in major depressive disorder. Clin Neuropharmacol (2007) 30(3):136-144.
18. Muhonen LH, Lönnqvist J, Juva K, Alho H: Double-blind, randomized comparison of memantine and escitalopram for the treatment of major depressive disorder comorbid with alcohol dependence. J Clin Psychiatry (2008) 69(3):392-399.
19. Zarate CA Jr, Singh JB, Quiroz JA, De Jesus G, Denicoff KK, Luckenbaugh DA, Manji HK, Charney DS: A double-blind, placebo controlled study of memantine in the treatment of major depression. Am J Psychiatry (2006) 163(1):153-155.
20. Preskorn S, Baker B, Omo K, Kolluri S, Menniti FS, Landen JW: A placebo-controlled trial of the NR2B subunit specific NMDA antagonist CP-101,606 plus paroxetine for treatment resistant depression (TRD). Annual Conference of the American Psychological Association, San Francisco, CA, USA (2007):Abs 154.
21. Choudary PV, Molnar M, Evans SJ, Tomita H, Li JZ, Vawter MP, Myers RM, Bunney WE Jr, Akil H, Watson SJ, Jones EG: Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. Proc Natl Acad Sci USA (2005) 102(43):15653-15658.
22. Beneyto M, Kristiansen LV, Oni-Orisan A, McCullumsmith RE, Meador-Woodruff JH: Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders. Neuropsychopharmacology (2007) 32(9):1888-1902.
23. Voss OP, Milne S, Sharkey J, O'Neill MJ, McCulloch J: Molecular mechanisms of neurite growth with AMPA receptor potentiation. Neuropharmacology (2007) 52(2):590-597.
24. Bleakman D, Alt A, Witkin JM: AMPA receptors in the therapeutic management of depression. CNS Neurol Disord Drug Targets (2007) 6(2):117-126.
25. Chourbaji S, Vogt MA, Fumagalli F, Sohr R, Frasca A, Brandwein C, Hörtnagl H, Riva MA, Sprengel R, Gass P: AMPA receptor subunit 1 (GluR-A) knockout mice model the glutamate hypothesis of depression. FASEB J (2008): epublished ahead of print. doi: 10.1096/fj.08-106450
26. Gould TD, O'Donnell KC, Dow ER, Du J, Chen G, Manji HK: Involvement of AMPA receptors in the antidepressant-like effects of lithium in the mouse tail suspension test and forced swim test. Neuropharmacology (2008) 54(3):577-587.
27. Sanacora G, Zarate CA, Krystal JH, Manji HK: Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov (2008) 7(5):426-437.
28. Shytle RD, Silver AA, Lukas RJ, Newman MB, Sheehan DV, Sanberg PR: Nicotinic acetylcholine receptors as targets for antidepressants. Mol Psychiatry (2002) 7(6):525-535.
29. Picciotto MR, Addy NA, Mineur YS, Brunzell DH: It is not "either/or": Activation and desensitization of nicotinic acetylcholine receptors both contribute to behaviors related to nicotine addiction and mood. Prog Neurobiol (2008) 84(4):329-342. • A comprehensive review of potential mechanisms underlying antidepressant-like effects of nAChR agonists and antagonists.
30. Semba J, Mataki C, Yamada S, Nankai M, Toru M: Antidepressant like effects of chronic nicotine on learned helplessness paradigm in rats. Biol Psychiatry (1998) 43(5):389-391.
31. Ferguson SM, Brodkin JD, Lloyd GK, Menzaghi F: Antidepressant-like effects of the subtype-selective nicotinic acetylcholine receptor agonist, SIB-1508Y, in the learned helplessness rat model of depression. Psychopharmacology (Berl) (2000) 152(3):295-303.
32. Buckley MJ, Surowy C, Meyer M, Curzon P: Mechanism of action of A-85380 in an animal model of depression. Prog Neuropsychopharmacol Biol Psychiatry (2004) 28(4):723-730.
33. Popik P, Kozela E, Krawczyk M: Nicotine and nicotinic receptor antagonists potentiate the antidepressant-like effects of imipramine and citalopram. Br J Pharmacol (2003) 139(6):1196-1202.
34. Murphy JM, Horton NJ, Monson RR, Laird NM, Sobol AM, Leighton AH: Cigarette smoking in relation to depression: Historical trends from the Stirling County Study. Am J Psychiatry (2003) 160(9):1663- 1669.
35. Glassman AH, Covey LS, Stetner F, Rivelli S: Smoking cessation and the course of major depression: A follow-up study. Lancet (2001) 357(9272):1929-1932.
36. Salín-Pascual RJ, Rosas M, Jimenez-Genchi A, Rivera-Meza BL, Delgado-Parra V: Antidepressant effect of transdermal nicotine patches in nonsmoking patients with major depression. J Clin Psychiatry (1996) 57(9):387-389.
37. Mineur YS, Somenzi O, Picciotto MR: Cytisine, a partial agonist of high-affinity nicotinic acetylcholine receptors, has antidepressant-like properties in male C57BL/6J mice. Neuropharmacology (2007) 52(5):1256-1262.
38. Papke RL, Sanberg PR, Shytle RD: Analysis of mecamylamine stereoisomers on human nicotinic receptor subtypes. J Pharmacol Exp Ther (2001) 297(2):646-656.
39. Caldarone BJ, Harrist A, Cleary MA, Beech RD, King SL, Picciotto MR: High-affinity nicotinic acetylcholine receptors are required for antidepressant effects of amitriptyline on behavior and hippocampal cell proliferation. Biol Psychiatry (2004) 56(9):657-664.
40. Rabenstein RL, Caldarone BJ, Picciotto MR: The nicotinic antagonist mecamylamine has antidepressant-like effects in wild-type but not β2- or α7-nicotinic acetylcholine receptor subunit knockout mice. Psychopharmacology (Berl) (2006) 189(3):395-401.
41. Drisdel RC, Sharp D, Henderson T, Hales TG, Green WN: High affinity binding of epibatidine to serotonin type 3 receptors. J Biol Chem (2008) 283(15):9659-9665.
42. Pichat P, Bergis OE, Terranova JP, Urani A, Duarte C, Santucci V, Gueudet C, Voltz C, Steinberg R, Stemmelin J, Oury-Donat F et al: SSR180711, a novel selective α7 nicotinic receptor partial agonist: (II) Efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia. Neuropsychopharmacology (2007) 32(1):17-34.
43. Targacept Inc: Targacept presents data from TRIDMAC trial showing positive effects of mecamylamine as augmentation treatment for depressed patients. Press release (2007) July 24.
44. Targacept Inc: Targacept initiates phase 2b clinical trial of TC-5214 as augmentation treatment in major depressive disorder. Press Release (2008) July 21.
45. Thompson AJ, Lummis SC: The 5-HT3 receptor as a therapeutic target. Expert Opin Ther Targets (2007) 11(4):527-540.
46. 129Ser) with major depression in women, and suggests that the naturally occurring polymorphism may have a protective role against development of major depression.
47. 3 receptors against the development of depression.
48. 3 receptor differentially affects behavior of males and females in the Porsolt forced swim and defensive withdrawal tests. Behav Brain Res (2004) 153(2):527-535.
49. 2X receptors. Physiol Rev (2002) 82(4):1013-1067.
50. 7 receptors in the nervous system. Prog Neurobiol (2006) 78(6):327-346.
51. 7 receptors caused by either genetic or environmental factors may lead to the development of depressive disorder.
52. 7, a gene coding for a purinergic ligand-gated ion channel, is associated with major depressive disorder. Hum Mol Genet (2006) 15(16):2438-2445.
53. 7 as a susceptibility gene to bipolar affective disorder. Am J Med Genet B Neuropsychiatr Genet (2006) 141B(4):374-382.
54. 7 receptor as a therapeutic target. Expert Opin Ther Targets (2008) 12(5):647-661
55. Gutman GA, Chandy KG, Grissmer S, Lazdunski M, McKinnon D, Pardo LA, Robertson GA, Rudy B, Sanguinetti MC, Stühmer W, Wang X: International Union of Pharmacology. LIII. Nomenclature and molecular relationships of voltage-gated potassium channels. Pharmacol Rev (2005) 57(4):473-508.
56. 2P channel TREK-1. Eur Biophys J (2008): epublished ahead of print. doi: 10.1007/s00249-008-0318-8
57. Kaster MP, Ferreira PK, Santos AR, Rodrigues AL: Effects of potassium channel inhibitors in the forced swimming test: Possible involvement of L-arginine-nitric oxide-soluble guanylate cyclase pathway. Behav Brain Res (2005) 165(2):204-209.
58. v7 channels: Interaction with dopaminergic and serotonergic neurotransmission in the CNS. J Physiol (2008) 586(7):1823- 1832.
59. v7 channels. J Pharmacol Exp Ther (2005) 314(1):282-292.
60. Munro G, Erichsen HK, Mirza NR: Pharmacological comparison of anticonvulsant drugs in animal models of persistent pain and anxiety. Neuropharmacology (2007) 53(5):609-618.
61. V7 disorders: Breakdown of a subthreshold brake. J Physiol (2008) 586(7):1791-1801.
62. Heurteaux C, Lucas G, Guy N, El Yacoubi M, Thümmler S, Peng XD, Noble F, Blondeau N, Widmann C, Borsotto M, Gobbi G et al: Deletion of the background potassium channel TREK-1 results in a depression-resistant phenotype. Nat Neurosci (2006) 9(9):1134-1141. • Provides the first description and extensive characterization of TREK-1 null mice. Deletion of TREK-1 resulted in mice that exhibited antidepressant-like behavior in multiple models, and showed a blunted endocrine response to stress, an increase in SSRI-evoked neurogenesis and an increase in raphe nucleus firing frequency.
63. Gordon JA, Hen R: TREKing toward new antidepressants. Nat Neurosci (2006) 9(9):1081-1083.
64. + channel in adrenocortical cells is TREK-1. J Biol Chem (2002) 277(51):49186-49199.
65. + channels and stimulates cortisol secretion from adrenocortical cells. Biochem Biophys Res Commun (2008) 370(4):623-628.
66. Kennard LE, Chumbley JR, Ranatunga KM, Armstrong SJ, Veale EL, Mathie A: Inhibition of the human two-pore domain potassium channel, TREK-1, by fluoxetine and its metabolite norfluoxetine. Br J Pharmacol (2005) 144(6):821-829.
67. 2+ channel antagonists. J Pharmacol Exp Ther (2007) 323(1):39-48.
68. Bymaster FP, McNamara RK, Tran PV: New approaches to developing antidepressants by enhancing monoaminergic neurotransmission. Expert Opin Investig Drugs (2003) 12(4):531-543.
69. 11C] DASB positron emission tomography study. Am J Psychiatry (2004) 161(5):826-835.
70. Perlis RH, Moorjani P, Fagerness J, Purcell S, Trivedi MH, Fava M, Rush AJ, Smoller JW: Pharmacogenetic analysis of genes implicated in rodent models of antidepressant response: Association of TREK1 and treatment resistance in the STAR*D study. Neuropsychopharmacology (2008): epublished ahead of print. doi:10.1038/npp.2008.6
71. Triggle DJ: Calcium channel antagonists: Clinical uses - past, present and future. Biochem Pharmacol (2007) 74(1):1-9.
72. Kraus RL, Yuxing L, Jovanovska A, Renger JJ: Trazodone inhibits T-type calcium channels. Neuropharmacology (2007) 53(2):308-317.
73. 3 subunit. Brain Res (2007) 1160:102-112.
74. 2δ) subunit as a target for antiepileptic drug discovery. Epilepsy Res (2007) 73(2):137-150.
75. Owen RT: Pregabalin: Its efficacy, safety and tolerability profile in generalized anxiety. Drugs Today (2007) 43(9):601-610.
76. Coryell MW, Ziemann AE, Westmoreland PJ, Haenfler JM, Kurjakovic Z, Zha X-M, Price M, Schnizler MK, Wemmie JA: Targeting ASIC1a reduces innate fear and alters neuronal activity in the fear circuit. Biol Psychiatry (2007) 62(10):1140-1148.
77. Marsch R, Foeller E, Rammes G, Bunck M, Kössl M, Holsboer F, Zieglgänsberger W, Landgraf R, Lutz B, Wotjak CT: Reduced anxiety, conditioned fear, and hippocampal long-term potentiation in transient receptor potential vanilloid type 1 receptor-deficient mice. J Neurosci (2007) 27(4):832-839.
78. Wemmie JA, Askwith CC, Lamani E, Cassell MD, Freeman JH Jr, Welsh MJ: Acid-sensing ion channel 1 is localized in brain regions with high synaptic density and contributes to fear conditioning. J Neurosci (2003) 23(13):5496-5502.